M42 is a global health champion powered by artificial intelligence (AI), technology and genomics to advance innovation in health for people and the planet. Headquartered in Abu Dhabi, M42 combines its specialized, state-of-the-art facilities with integrated health solutions like genomics and biobanks, and harnesses advanced technologies to deliver precise, preventive and predictive care, to impactfully disrupt traditional healthcare models and positively impact lives globally.
Established in 2023, following the coming together of G42 Healthcare and Mubadala Health, M42 has more than 480 facilities in 26 countries and over 20,000 employees. M42 includes renowned healthcare providers including Cleveland Clinic Abu Dhabi, Danat Al Emarat, Diaverum, Imperial College London Diabetes Centre, Sheikh Sultan bin Zayed Hospital, and Moorfields Eye Hospital Abu Dhabi. As well as operating the Emirati Genome Programme, M42 runs Abu Dhabi BioBank and Abu Dhabi Health Data Services (ADHDS), a global tech-enabled healthcare company operating Malaffi.
#3 Largest dialysis provider globally
M42’s Diaverum globally provides vital kidney-related treatment through an extensive dialysis center network.
480 World-class facilities
Offering a broad spectrum of top-quality medical services, ensuring accessible and comprehensive care for patients across various specialties.
120 Petabyte data storage
Securely storing vast medical data for advanced analytics, AI, and research driving healthcare advancements and improved outcomes.
900K+ Biobank samples stored
A cornerstone for groundbreaking discoveries and pioneering medical solutions with a potential for life-changing impact.
400K Sequencing capacity per year
Positioning M42 at the forefront of genomics advancements, poised for significant contributions to understanding and improving human health.
700K+ Genome samples sequenced
Offering valuable insights into Emirati genetics, paving the way for personalized healthcare and region-specific medical advancements.
